PEDIATRICS Vol. 107 No. 5 May 2001, p. e66
ELECTRONIC ARTICLE:
Serologic Evidence for Cryptococcus neoformans
Infection in Early Childhood
,
,
, §,
, §
From the Departments of * Pediatrics,
Medicine, and
§ Microbiology and Immunology, and the
Bronx Children's Hospital at
Montefiore, Albert Einstein College of Medicine, Bronx, New York.
| |
ABSTRACT |
|---|
|
|
|---|
Objective. Cryptococcus neoformans is an important cause of central nervous system infection in adults with acquired immunodeficiency syndrome (AIDS) but an unusual cause of disease in children with AIDS. The basis for this age-related difference in incidence is not known but may be caused by differences in exposure or immune response. The objective of this study was to determine whether the low prevalence of cryptococcal disease among children is related to a lack of exposure to C neoformans.
Methods. Sera were obtained from 185 immunocompetent individuals ranging in age from 1 week to 21 years who were being evaluated in an urban emergency department. Sera were analyzed for antibodies to C neoformans and Candida albicans proteins by immunoblotting. Immunoblot patterns were compared with those obtained from sera of patients with cryptococcosis (n = 10) and workers in a laboratory devoted to the study of C neoformans. The specificity of our results was confirmed by several approaches, including antibody absorption and blocking studies. Sera were also analyzed for the presence of cryptococcal polysaccharide by both enzyme-linked immunosorbent assay and latex agglutination assays.
Results. Sera from children 1.1 to 2 years old
demonstrated minimal reactivity to C neoformans
proteins. In contrast, the majority of sera from children >2 years old
recognized many (
6) C neoformans proteins. For
children between 2.1 and 5 years old, 56% of sera (n = 25) reacted with many proteins, whereas for
children >5 years old (n = 120), 70% of samples
reacted with many proteins. Reactivity was decreased by absorbing sera
with C neoformans extracts or by preincubating blots
with sera from experimentally infected but not from control rats.
Reactivity to C neoformans proteins did not correlate
with reactivity to C albicans proteins,
which was common in sera from children between the ages of 1.1 and 2 years. Cryptococcal polysaccharide was detected at a titer of 1:16
(~10 ng/mL) in the sera of 1 child, a 5.6-year-old boy who presented
to the emergency department with vomiting.
Conclusions. Our findings provide both indirect and direct evidence of C neoformans infection in immunocompetent children. Our results indicate that C neoformans infects a majority of children living in the Bronx after 2 years old. These results are consistent with several observations: the ubiquitous nature of C neoformans in the environment, including its association with pigeon excreta; the large number of pigeons in urban areas; and the increased likelihood of environmental exposure for children once they have learned to walk. The signs and symptoms associated with C neoformans infection in immunocompetent children remained to be determined. Primary pulmonary cryptococcosis may be asymptomatic or produce symptoms confused with viral infections and, therefore, not recognized as a fungal infection. Our results suggest that the low incidence of symptomatic cryptococcal disease in children with AIDS is not a result of lack of exposure to C neoformans. These findings have important implications for C neoformans pathogenesis and the development of vaccine strategies. Key words: Cryptococcus neoformans, fungal infection, human immunodeficiency virus, serology.
Cryptococcus neoformans is remarkable for its
ability to cause disease in immunocompromised individuals. C
neoformans disease occurs in 6% to 8% of adult patients with
acquired immunodeficiency syndrome (AIDS), making it the most common
central nervous system fungal infection associated with advanced human
immunodeficiency virus (HIV) infection.1 In contrast, the
prevalence of C neoformans infection in children with AIDS is ~1%.2,3 The basis for this discrepancy is
not understood but could be caused by differences in exposure or in the
immune response.
C neoformans infection is believed to be acquired via
inhalation of aerosolized particles from the environment. Serologic studies using a polysaccharide-based enzyme-linked immunosorbent assay
(ELISA) suggest that subclinical infection is very common among
immunocompetent adults.4,5 Recently, we have used an
immunoblot technique to confirm these findings.6 The
potential advantages of this approach relate to the enhanced specificity of analyzing antibody responses to multiple proteins. Furthermore, polysaccharides are typically poor immunogens for children, which could limit the sensitivity of cryptococcal
polysaccharide-based assays in pediatric studies. In this study, we
used this approach to determine whether immunocompetent children are
infected with C neoformans and to define the age at which
infection occurs.
Study Population
One hundred eighty-five individuals ranging in age from 1 week
to 21 years who underwent diagnostic blood studies while being evaluated at the pediatric emergency department at the Montefiore Medical Center in the Bronx from July 1998 to February 1999 had their
excess blood collected from the laboratory for this seroprevalence investigation. Age, ethnicity, sex, chief complaint, and presence of
chronic illnesses were recorded. Immunocompromised children at risk for
cryptococcosis were excluded. Sera from 10 patients with
cryptococcosis, with and without AIDS, were also obtained. For the 5 patients with AIDS, sera were obtained from individuals in the
Multi-Center AIDS Cohort Study who were found to have cryptococcal polysaccharide in their sera.7 Sera from patients with
cryptococcosis but without HIV were donations. Sera were also obtained
from individuals (n = 11) who worked for at least 2 months in a laboratory devoted to the study of C neoformans at the Albert Einstein College of Medicine (Bronx, NY). All samples were obtained according to the practices and standards of the institutional review boards at Albert Einstein College of Medicine and
Montefiore Medical Center. Rats were endotracheally infected with
C neoformans strain H-99 as described8 and sera
were obtained at 3 months of infection.
Fungal Strains
C neoformans strains 24067 (serotype D), H-99
(serotype A), and CAP 67 (unencapsulated strain) were obtained from the
American Type Culture Collection (Manassas, VA), John Perfect (Durham, NC), and Eric Jacobson (Richmond, VA), respectively.
Candida albicans SC5314 was obtained from M. Ghannoum
(Cleveland, OH).
Fungal Protein Extracts
Crude protein extracts of C neoformans and C
albicans were obtained as described as previously.6
Briefly, fungi were grown in Sabouraud dextrose broth for 1 to 2 days
at 30°C or 37°C. Cells were collected by centrifugation, disrupted
by serial vortexing with glass beads, and sonicated in a buffer
containing protease inhibitors.
Immunoblotting
Immunoblotting of sera against fungal protein extracts was
performed as described.6 Immunoglobulin G antibodies
reactive to cryptococcal protein were detected with alkaline
phosphatase-labeled goat anti-human immunoglobulin G (Southern
Biotechnology Associates, Birmingham, AL). For all blots, serum from a
laboratory worker was used as a positive control and omission of sera
was used as a negative control. Several approaches were taken to ensure
the specificity of our methods. Absorption studies were performed in
which representative sera were incubated with C neoformans
protein extracts, either in solution or immobilized on nitrocellulose
membranes, and then blotted against C neoformans proteins.
In addition, in some studies C neoformans blots were
incubated with sera from uninfected rats or rats with experimental
pulmonary cryptococcosis,6,9 before incubation with human
sera. In previous studies, we have shown that the sera from uninfected
rats exhibit no reactivity against cryptococcal proteins, whereas the
sera from rats infected with C neoformans react with
multiple proteins.6 For C albicans immunoblots,
81 representative serum samples were analyzed.
Serum Polysaccharide Levels
Sera were digested with pronase and screened for cryptococcal
polysaccharide by latex agglutination using the CALAS system (Meridian
Diagnostics, Cincinnati, OH). Specimens that were found to have
polysaccharide on initial testing were retested to confirm initial
findings using a previously described capture ELISA.10
Defining a Reactive Pattern
Western blot profiles of individuals with cryptococcosis and
workers in a C neoformans laboratory were used to define a
reactive pattern. Laboratory workers were used because of an increased likelihood of exposure and previous studies that have shown strong delayed-type hypersensitivity reactions to C neoformans
extracts in these individuals.11 These sera most commonly
recognized 9 proteins with approximate molecular weights of: 139, 116, 111, 106, 98, 85, 74, 64, and 46 kDa (Fig
1). Sera from 60% of patients with
cryptococcosis (n = 10) and from 91% of individuals
working in a C neoformans laboratory (n = 11) reacted with many (
![]()
METHODS
Top
Abstract
Methods
Results
Discussion
Conclusion
References
6) of the 9 designated proteins (Fig 1).
Antibodies to these proteins in reactive samples were present
regardless of which strain of C neoformans was used to
prepare the extract (24067, H-99, or Cap 67) or the temperature at
which C neoformans was grown (30°C vs 37°C). Most of
these bands were of the same approximate size as those previously described in patients with cryptococcosis.12 Furthermore,
6 of these bands (116, 111, 106, 85, 74, and 64 kDa) were of the same
approximate size as those recognized by the sera from rats with
experimental cryptococcosis.6

View larger version (98K):
[in a new window]
Fig. 1.
Immunoblots against C neoformans extracts.
Representative immunoblots of sera from: HIV+ and
HIV
patients with cryptococcosis, individuals who work in
a laboratory devoted to the study of C neoformans, and
children without a defined exposure to C neoformans.
Arrows point to bands that were studied.
Data Analysis
The number of reactive bands in the immunoblots of sera from
children of various ages were compared by the Mann-Whitney rank sum
test. Sera reacting with
6 of the 9 designated bands (
67%) were
classified as reacting with many bands. Sera reacting with 3 to 5 bands
were classified as reacting with some, and sera reacting with 0 to 2 bands were classified as reacting with few to no bands.
2 analysis was used to compare the reactivity
between the various age groups according to this classification scheme.
P values
.05 were considered significant.
| |
RESULTS |
|---|
|
|
|---|
Patient Demographics
Mean and median ages of children were 9.5 and 9.2 years, respectively. Fifty-two percent of the children were Hispanic, 31% black, 8% white, 3% Asian, and 6% were either nonspecified or listed as other.
Children
Variation among the reactivity of sera from children against
C neoformans proteins was observed (Fig 1). Sera from children 1.1 to 2 years old demonstrated the least reactivity among the
various age cohort groups (Fig 2). The
majority of samples (64.3%) from this age group (n = 14) reacted with few or no (0-2) protein bands, with a median of 1 recognized protein. Sera obtained from older children demonstrated
significantly more reactivity. For children between the ages of 2.1 and
5 years old, 56% of sera (n = 25) reacted with many
proteins, with a median of 6 recognized proteins (Mann-Whitney rank sum
test, P = .008;
2,
P = .009). For children older than 5 years of age
(n = 120), 70% of samples reacted with many proteins,
with a median of 7 recognized proteins.
|
In general, the pattern of reactivity against individual proteins paralleled the overall increase in reactivity for sera from the various age groups (Fig 3). The percent of sera exhibiting reactivity against several proteins (139, 116, 111, 106, and 98 kDa) was particularly low for children between the ages of 1.1 and 2 years. Reactivity against these proteins was lower in this age group compared with sera from all age groups including children ages 0 to 1 year (Mann-Whitney rank sum, P = .036).
|
Immunoblotting Against C albicans
Children
Exposure to C albicans, another fungal pathogen, is
common among children. We analyzed the reactivity of our study samples against C albicans to determine whether the observed
reactivity against C neoformans was the result of antibodies
against C albicans. The reactivity of sera from children for
C albicans proteins was greater in both intensity and
diversity than for C neoformans proteins. Many sera produced
smears in certain regions of the blot, making a determination of
individual bands in these regions not possible. For this analysis,
these smears were considered as individual proteins, although they
likely represent multiple reactive proteins. In contrast to the low
level of reactivity observed for sera against C neoformans
in the 1.1- to 2-year-old age group, 75% of samples (n = 12) from this age group recognized many (
6) C albicans
proteins (Fig 2). The median number of proteins recognized by sera in
this age groups was 8. The least amount of reactivity against C
albicans was observed in children in the 0- to 1-year-old age
group. In this age group, 39.1% of samples (n = 23)
reacted with many proteins. Of the 11 sera that reacted with few to no
C albicans proteins, 3 samples recognized many C
neoformans proteins.
Absorption Studies Incubation of sera with C neoformans protein in solution or by serial blotting reduced the reactivity of sera against C neoformans proteins (data not shown). In addition, preincubation of C neoformans blots with sera from rats with experimental cryptococcosis but not uninfected control rats resulted in a reduction in reactivity (Fig 4)
|
Serum Polysaccharide Of the 185 serum samples, 1 sample was found to contain polysaccharide by both latex agglutination and ELISA techniques. This serum came from a 5.6-year-old boy who presented to the emergency department with vomiting. The latex titer and antigen concentration for this sample were 1:16 and 10 ng/mL, respectively. The sera of this child reacted with 8 of the 9 designated bands.
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we identified 9 bands that were most commonly
recognized by sera from individuals with cryptococcosis and individuals with a likelihood of exposure to C neoformans. Most of these
bands were of the same approximate size as those previously described in other human and animal studies.6,12 Interestingly, some
patients with cryptococcosis (3/5 HIV+ and 1/5
HIV
) exhibited a diminished antibody response
to C neoformans that likely reflects the great degree of
immunosuppression in these patients. Among immunocompetent children
without a defined exposure to C neoformans, sera from
children aged 1.1 to 2 years demonstrated minimal reactivity against
C neoformans proteins. We have previously shown a high
prevalence of antibodies reactive to these bands in sera from
HIV
and HIV+ individuals
without cryptococcosis.6 The absence of reactivity in the
sera of these children served as a negative control for our assay. This
decreased reactivity in the sera was particularly prominent for several
bands (~139, 116, 111, 106, and 98 kDa). Overall, the observed
age-related pattern of reactivity against C neoformans
resembles that described for infections caused by a variety of
pediatric pathogens, where there is an initial decrease in sera
reactivity attributable to waning maternal antibody followed by an
increase in reactivity associated with subsequent
infection.13,14 Reactivity against C albicans
is increased in the sera from children ages 1.1 to 2 years relative to
the first year of life. This presumably reflects acquisition of C
albicans in the first year of life followed by an immune response
to candidal antigens.
Our findings suggest that most children residing in the Bronx are
infected with C neoformans after the second year of life. This age corresponds with increased mobility and independence of
children and increased environmental exposure. C neoformans is ubiquitous in the environment and can be isolated from soil contaminated with bird excreta as well as the surrounding
air.15 Regional differences in the incidence of
symptomatic cryptococcal infection for both HIV+
and HIV
individuals have been
described.16 It is conceivable that the high density of
people and pigeons in an urban environment like the Bronx contributes
to the early age and high prevalence of C neoformans
infection.
Although our findings could be interpreted to represent the acquisition of cross-reactive antibodies, several lines of evidence suggest that the observed antibody responses are the result of C neoformans infection. First, most of the proteins recognized by sera from children were of the same approximate size as those recognized by animals and humans with cryptococcosis.6,12 Second, the observed reactivity could be reduced by absorption with C neoformans proteins. Third, preincubation of blots with sera from rats with cryptococcosis but not controls reduced reactivity of pediatric sera. Fourth, the age distribution of antibody responses against C neoformans was remarkably different compared with the response against C albicans, which is a frequent cause of superficial skin infections in children. The increase in reactivity against C albicans in the 1.1- to 2-year old age group did not correlate with an in increase in reactivity against C neoformans, consistent with the notion that these responses are to independent microorganisms. Furthermore, sera from 3/11 children demonstrated minimal reactivity to C albicans proteins but reacted with many C neoformans proteins strongly arguing against cross-reactive antibodies as the explanation for our results. Finally, the detection of cryptococcal polysaccharide in the serum of 1 patient provided direct evidence of cryptococcal infection. Although rheumatoid factor reactions can cause false-positive latex agglutination tests, the use of pronase essentially eliminates this reaction.17 Furthermore, this is not a problem in the ELISA system that was used as a confirmatory method. False-positive latex agglutination tests have been reported in patients with disseminated trichosporon infection.18,19 Our patient, however, was immunocompetent and not at risk for this type of infection.
The findings of this study are consistent with the studies conducted by Abadi et al20 who found reactive antibodies to the cryptococcal polysaccharide in sera of children from the Bronx who did not have clinical cryptococcosis, regardless of HIV status. These antibodies were serogroup-specific and could not be absorbed by incubation with pneumococcal polysaccharide. In contrast, Speed and Kaldor21 found a low prevalence (~4%) of antibodies reactive with cryptococcal polysaccharide in the sera of Australian children (>5 years old) compared with a prevalence of ~65% in the sera obtained from adult blood donors. The basis for the discrepancy between these studies could be related to the differences in exposure and/or differences in methodology.
The diversity and persistence of the antibody profile in older children are consistent with either persistent or repeated C neoformans infections. We observed a similar pattern of antibody persistence in a rat model of chronic pulmonary infection.6,9 In this model, endotracheally infected rats developed small subpleural and interstitial granulomas in which C neoformans persisted for as long as 18 months after inoculation. Furthermore, an increasing amount of clinical and laboratory evidence supports the concept that C neoformans causes latent pulmonary infections that can be reactivated to produce central nervous system infection later in life. In the 1970s, Haugen and Baker22 described pulmonary granulomas containing C neoformans in a subset of autopsy studies performed on patients who lacked a history of C neoformans exposure. Recently, Fleuridor et al7 demonstrated the presence of antibodies to cryptococcal polysaccharide in HIV-infected patients who subsequently developed cryptococcosis. Finally, molecular typing studies have described significant discrepancies between environmental and clinical isolates. Molecular studies indicate that cryptococcosis in African individuals living in Europe are the result of reactivation of latent infection.23 In contrast, a case of apparent C neoformans infection from a pet cockatoo was recently reported24 suggesting that for some patients symptomatic C neoformans infection represents either a primary progressive infection or a reinfection.
| |
CONCLUSION |
|---|
|
|
|---|
Our findings indicate that children in an urban setting acquire antibodies reactive with C neoformans proteins after 2 years old and that these antibodies persist throughout childhood. These findings are consistent with either repeated or persistent C neoformans infection. A prospective study is needed to define the symptoms associated with primary C neoformans infection in children. Primary pulmonary infection could be asymptomatic or could produce symptoms confused with viral infections and, therefore, not recognized clinically, similar to infections caused by other endemic mycoses. The findings of this study suggest that the low incidence of symptomatic cryptococcal disease in children with AIDS is not the result of a lack of exposure to C neoformans; nevertheless, quantitative and qualitative differences in the exposure to C neoformans between children and adults may exist. Persistent C neoformans infection could have important implications. In a rat model, persistent pulmonary cryptococcosis is associated with down-modulation of both humoral and cellular inflammatory responses.9 Furthermore, infection at an early age will have important implications on the approach to vaccination25,26 to prevent C neoformans infection.
| |
ACKNOWLEDGMENTS |
|---|
Dr Goldman is supported by National Institutes of Health Grants AI1300 and HL64547; Dr Pirofski is supported by National Institutes of Health Grants AI35370 and AI45459; and Dr Casadevall is supported by National Institutes of Health Grants AI13142, HL59842, and AI33774.
We thank Jaime E. Fergie, MD, and Charlotte Cunningham-Rundles, MD, PhD, of Driscoll Children's Hospital (Corpus Christi, Texas) and Mount Sinai Medical Center (New York, New York), respectively, for their donations of sera from non-HIV-infected patients with cryptococcosis.
We also thank Drs N. Littman, J. Glaser, and B. C. Fries for their careful proofreading of this manuscript.
| |
FOOTNOTES |
|---|
Received for publication Aug 14, 2000; accepted Nov 27, 2000.
Reprint requests to (D.L.G.) Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461. E-mail: dgoldma{at}aecom.yu.edu
| |
ABBREVIATIONS |
|---|
AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; ELISA, enzyme-linked immunosorbent assay.
| |
REFERENCES |
|---|
|
|
|---|
- Currie BP, Casadevall A Estimation of the prevalence of cryptococcal infection among HIV-infected individuals in New York City. Clin Infect Dis 1994; 19:1029-1033 [Medline]
- Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ Cryptococcosis in human immunodeficency virus-infected children. Pediatr Infect Dis J 1996; 15:796-800 [CrossRef][Medline]
- Abadi J, Nachman S, Kressel AB, Pirofski L-A Cryptococcosis in children with AIDS. Clin Infect Dis 1999; 28:309-313 [Medline]
- Houpt DC, Pfrommer GST, Young BJ, Larson TA, Kozel TR Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun 1994; 62:3857-2864
-
DeShaw M,
Pirofski L-A
Antibodies to the Cryptococcus
neoformans capsular glucuronoxylomannan are ubiquitous in serum
from HIV+ and HIV
individuals.
Clin Exp Immunol
1995;
99:425-432 [Medline] -
Chen L,
Goldman DL,
Doering TL,
Pirofski L-A,
Casadevall A
The
antibody response to Cryptococcus neoformans proteins in
rodents and humans.
Infect Immun
1999;
67:2218-2224
[Abstract/Free Full Text] - Fleuridor R, Lyles RH, Pirofski L Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J Infect Dis 1999; 180:1526-1535 [CrossRef][Medline]
-
Goldman D,
Lee SC,
Casadevall A
Pathogenesis of pulmonary
Cryptococcus neoformans infection in the rat.
Infect
Immun
1994;
62:4755-4761
[Abstract/Free Full Text] -
Goldman DL,
Lee SC,
Mednick AJ,
Montella L,
Casadevall A
Persistent
Cryptococcus neoformans pulmonary infection in the rat is
associated with intracellular parasitism, decreased inducible nitric
oxide synthase expression and altered antibody responsiveness to
cryptococcal polysaccharide.
Infect Immun
2000;
68:832-838
[Abstract/Free Full Text] - Casadevall A, Mukherjee J, Scharff MD Monoclonal antibody ELISAs for cryptococcal polysaccharide. J Immunol Methods 1992; 154:27-35 [CrossRef][Medline]
- Atkinson AJ Jr, Bennett JE Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am Rev Respir Dis 1968; 97:637-643 [Medline]
- Hamilton AJ, Figueroa JI, Jeavons L, Seaton RA Recognition of cytoplasmic yeast antigens of Cryptococcus neoformans and Cryptococcus neoformans var. gattii by immune human sera. FEMS Immunol Med Microbiol 1997; 17:111-119 [CrossRef][Medline]
- Schneerson R, Rodrigues LD, Parke JC, Robbins JB Immunity to disease caused by Haemophilus influenzae type b. J Immunol 1971; 1:1081-1089
- Goldschneider I, Gotschlich EC, Artenstein M Human immunity to the meningococcus. J Exp Med 1969; 129:1327-1348 [Abstract]
- Littman ML Cryptococcosis (torulosis). Am J Med 1959; 27:976-998 [CrossRef][Medline]
- Hajjeh RA, Conn LA, Stephens DS, Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179:449-454 [CrossRef][Medline]
- Stockman L, Roberts GD Specificity of the latex test for cryptococcal antigen: a rapid, simple method for eliminating interference factors. J Clin Microbiol 1992; 16:965-967
-
McManus EJ,
Jones JM
Detection of a Trichosporon beigelii
antigen cross-reactive with Cryptococcus neoformans capsular
polysaccharide in serum from a patient with disseminated
Trichosporon infection.
J Clin Microbiol
1985;
21:681-685
[Abstract/Free Full Text] - Campbell CK, Payne AL, Teall AJ, Brownwell A, Mackenzie DWR Cryptococcal latex agglutination antigen test positive in patient with Trichosporon beigelii infection. Lancet 1985; 2:43-44 [Medline]
- Abadi J, Pirofski L-A Antibodies reactive with the cryptococcal polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J Infect Dis 1999; 180:915-919 [CrossRef][Medline]
- Speed BR, Kaldor J Rarity of cryptococcal infection in children. Pediatr Infect Dis J 1997; 16:536-537 [CrossRef][Medline]
- Haugen RK, Baker RD The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am J Clin Pathol 1954; 24:1381-1390 [Medline]
-
Garcia-Hermoso D,
Janbon G,
Dromer F
Epidemiological evidence for
dormant Cryptococcus neoformans infection.
J Clin
Microbiol
1999;
37:3204-3209
[Abstract/Free Full Text] -
Nosanchuk JD,
Shoham S,
Fries BC,
Shapiro DS,
Levitz SM,
Casadevall A
Evidence of zoonotic transmisssion of Cryptococcus
neoformans from a pet cockatoo to an immunocompromised patient.
Ann Intern Med
2000;
132:205-208
[Abstract/Free Full Text] -
Devi SJN,
Schneerson R,
Egan W,
Cryptococcus
neoformans serotype A glucuronoxylomannan-protein conjugate
vaccines: synthesis, characterization, and immunogenicity.
Infect
Immun
1991;
59:3700-3707
[Abstract/Free Full Text] - Williamson PR, Bennett JE, Polis MA, Robbins JB, Schneerson R Immunogenicity and safety of a conjugate glucuronoxylomannan-tetanus conjugate vaccine in volunteers [abstract]. Clin Infect Dis 1993; 17:540
Pediatrics (ISSN 0031 4005). Copyright ©2001 by the American Academy of Pediatrics
This article has been cited by other articles:
![]() |
A. P. Litvintseva and T. G. Mitchell Most Environmental Isolates of Cryptococcus neoformans var. grubii (Serotype A) Are Not Lethal for Mice Infect. Immun., August 1, 2009; 77(8): 3188 - 3195. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Saha, D. L. Goldman, X. Shao, A. Casadevall, S. Husain, A. P. Limaye, M. Lyon, J. Somani, K. Pursell, T. L. Pruett, et al. Serologic Evidence for Reactivation of Cryptococcosis in Solid-Organ Transplant Recipients Clin. Vaccine Immunol., December 1, 2007; 14(12): 1550 - 1554. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jalali, L. Ng, N. Singh, and L.-a. Pirofski Antibody Response to Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan in Patients after Solid-Organ Transplantation. Clin. Vaccine Immunol., July 1, 2006; 13(7): 740 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-A. Pirofski Of Mice and Men, Revisited: New Insights into an Ancient Molecule from Studies of Complement Activation by Cryptococcus neoformans. Infect. Immun., June 1, 2006; 74(6): 3079 - 3084. [Full Text] [PDF] |
||||
![]() |
T. Bicanic and T. S. Harrison Cryptococcal meningitis Br. Med. Bull., April 18, 2005; 72(1): 99 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Maitta, K. Datta, Q. Chang, R. X. Luo, B. Witover, K. Subramaniam, and L.-a. Pirofski Protective and Nonprotective Human Immunoglobulin M Monoclonal Antibodies to Cryptococcus neoformans Glucuronoxylomannan Manifest Different Specificities and Gene Use Profiles Infect. Immun., August 1, 2004; 72(8): 4810 - 4818. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Maitta, K. Datta, A. Lees, S. S. Belouski, and L.-a. Pirofski Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice Infect. Immun., January 1, 2004; 72(1): 196 - 208. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||










